Introduction {#Sec1}
============

Age-associated physiological changes result in pharmacokinetic and pharmacodynamic alterations in the body among elderly people. Pharmacodynamic changes usually increase the sensitivity to several drug classes, for example, psychotropic drugs \[[@CR1]\]. This leads to altered drug effect, increased vulnerability to adverse drug reactions (ADRs) and drugs often exhibiting narrower therapeutic ranges \[[@CR1], [@CR2]\].

More pronounced changes in neurotransmitter substances, for example, acetylcholine and dopamine, have been observed in the central nervous system (CNS) among people with dementia than people without dementia \[[@CR3]\], and an association has been found between lowered serotonin levels and Alzheimer's disease \[[@CR4]\]. Additionally, there are reports indicating changes in the blood--brain barrier among people with Alzheimer's disease, which alter the possibility of drugs traversing the blood--brain barrier and reaching CNS. This may further alter drug response \[[@CR5]\]. Thus, elderly people with dementia are extremely sensitive to ADRs \[[@CR3]\].

Problems associated with drug treatment such as ADRs and potentially inappropriate drug use are common and are the reason for the high volume of hospitalisations among elderly people \[[@CR6]\]. People with dementia or cognitive impairment are at even greater risk, in which 41% of hospital admissions were judged to be attributable, or partially attributable, to drug-related problems (DRPs) \[[@CR7]\].

Drug--drug interactions (DDIs) defined as "when the effects of one drug are changed by the presence of another drug" \[[@CR8]\] are a significant cause of these DRPs. For example, one review found that DDIs were responsible for 4.8% of admissions among elderly people \[[@CR9]\]. Another study found that 17% of the ADRs causing hospitalisation were DDIs \[[@CR10]\]. Many hospitalisations caused by DDIs could be avoided \[[@CR11]\]. Increased risk of bleeding, prolongation of QT interval and hyperkalaemia are examples of the consequences of DDIs that expose elderly people with dementia to unnecessary risks if drug use is not properly monitored \[[@CR12], [@CR13]\].

Previous studies have found that inappropriate drugs according to age and inappropriate drugs according to renal function were prevalent in the study sample \[[@CR14], [@CR15]\]. It was also found that DDIs accounted for 6.9% of the drug-related hospitalisations in this population including elderly persons with dementia or cognitive impairment \[[@CR7]\].

The objective of this study was therefore to further assess drug use among people aged 65 years or older with dementia and cognitive impairment, more specifically to assess the occurrence and character of all clinically relevant DDIs prevalent at admission to hospital. A further objective was to investigate factors associated with clinically relevant DDIs in old people with dementia or cognitive impairment. To the best of our knowledge, no previous studies have investigated this before.

Methods {#Sec2}
=======

Settings and study design {#Sec3}
-------------------------

This cross-sectional study included the same persons involved in an intervention study \[[@CR16]\]. In the intervention study, elderly people with dementia or cognitive impairment were recruited from two hospitals in Northern Sweden in order to investigate if the rate of readmissions was reduced when clinical pharmacists were included in the healthcare team. People from the acute internal medicine ward and orthopaedic ward at Umeå University Hospital and people admitted to the medicine wards at the county hospital in Skellefteå were recruited. People aged 65 years or older with dementia or cognitive impairment admitted to the included wards between 9 January 2012 and 2 December 2014 were asked to participate in the study. In total, 473 persons were invited and 13 declined to participate \[[@CR16]\]. The present study population comprised both intervention and control groups at the time of index admission and before any intervention was performed. Persons with planned admissions (*n* = 1) and those who chose to withdraw from the intervention study before discharge (*n* = 1) were excluded, resulting in a final study sample of 458 persons.

Data extraction and definitions {#Sec4}
-------------------------------

The medications used by persons at admission (before any intervention was performed) to the included hospital wards were collected from the relevant person's medical records. Number of medications, drug formulation and administration, age, sex, type of dementia, Mini Mental State Examination (MMSE) score when available, type of accommodation and geographic location were also collected from the relevant person's medical records. Prescriptions with pro re nata dose were not included in the analysis (due to uncertainty about the dose) nor were over-the-counter drugs (due to lack of information in the medical records).

### Definitions {#Sec5}

Clinically relevant DDIs were identified using the Janusmed interaction database (formerly called Sfinx) \[[@CR17], [@CR18]\] in accordance with a previous study \[[@CR13]\]. This is a computerised system listing information about DDIs based on pairwise combination of drug substances. Information about interactions is updated 4--10 times per year. Drug interactions are classified into four different categories, A--D, dependent on clinical relevance, in which category C and D are considered to be clinically relevant DDIs (Table [1](#Tab1){ref-type="table"}). Moreover, the extent of documentation is recorded as 0--4 relating to the level of documentation (Table [1](#Tab1){ref-type="table"}) \[[@CR18]\].Table 1Classification of drug--drug interactions in Sweden, their clinical relevance and level of documentation \[[@CR18]\]Clinical relevance A: Clinically insignificant DDIs. B: Clinical relevance is unknown and/or varies. C: Clinically relevant DDIs that can be handled with individual dose adjustment, for example. D: Clinically relevant DDIs that should be avoided.Level of documentation 0: Data from studies including other drug substances with similar properties. 1: Data from incomplete case reports and/or in vitro studies. 2: Data from well-documented case reports. 3: Data from studies on healthy individuals and/or pilot studies on patients. 4: Data from controlled studies on relevant study population.*DDIs* drug--drug interactions

The interactions selected for this study focused on potentially clinically relevant DDIs type C, which may require dose adjustment, or type D, which should be avoided, consistent with previous studies \[[@CR19]--[@CR22]\] regardless of the level of documentation \[[@CR19]\]. DDIs were identified on drug substance level, meaning that drug formulations with several drug substances may give rise to several signals in combination with another drug substance. Identified DDIs were further categorised regarding pharmacological mechanisms according to Stockley's classification system (Table [2](#Tab2){ref-type="table"}) \[[@CR8]\]. The categorisation was based on the information given in the Janusmed interaction database and Stockley's Interaction Checker \[[@CR17], [@CR23]\]. Interactions with uncertainty of classification were categorised as "classification uncertain".Table 2Categorisation of pharmacological mechanism according to Stockley's classification system \[[@CR8]\]1. Pharmacokinetic interactions: 1.1 Drug absorption interactions. 1.2 Drug distribution interactions. 1.3 Drug metabolism (biotransformation) interactions.  1.3.1 Enzyme induction  1.3.2 Enzyme inhibition 1.4 Drug excretion interactions. 1.5 Drug transporter proteins.2. Pharmacodynamic interactions: 2.1 Additive or synergistic interactions. 2.2 Antagonistic or opposing interactions. 2.3 Drug or neurotransmitter uptake interactions.

Data analysis {#Sec6}
-------------

Descriptive statistics were used to present the characteristics of the study sample. Frequencies were calculated for dichotomous variables, i.e. sex, type of accommodation (living at home or in a nursing home) and geographic location (Skellefteå or Umeå). Continuous variables, i.e. age, number of medications at admission and MMSE score, were presented as mean values with standard deviation (SD).

Simple logistic regression analyses were conducted to investigate the association between the potential risk factors collected from the medical records, i.e. sex, age, number of medications at admission, MMSE score, type of accommodation and geographic location, and having at least one clinically relevant DDI. Multiple logistic regression analysis was conducted to investigate the association between sex, age and significant variables from the simple model, and having at least one potentially clinically relevant DDI. The results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). All analyses were conducted using IBM SPSS Statistics 24.

Results {#Sec7}
=======

Of 458 people in the study sample, 198 (43.2%) had at least one clinically relevant DDI. Among people with interactions, 195/198 (98.5%) had one or more DDI that required dose adjustment and 15/198 (7.6%) had at least one DDI that should be avoided. Among the study sample, 286 (62.4%) were women, the mean age was 83.2 ± 6.6, mean number of medications at admission was 7.7 ± 3.5 and mean MMSE score was 19.8 ± 4.7. A total of 307 (67.0%) of the study participants were living at home and 338 (73.8%) lived in Umeå municipality. An association was found in both the univariate and the multivariable model between having a higher number of medications prescribed and having at least one clinically relevant DDI. However, no associations were found between age, sex, MMSE score, type of accommodation or geographic location and the risk of having one or more clinically relevant DDIs in the logistic regression model(s) (Table [3](#Tab3){ref-type="table"}).Table 3Descriptive statistics of study population and comparison between people with and without clinically relevant DDIsCharacteristics of study sampleTotalDDI(s)No DDISimple OR (95% CI)Multiple OR (95% CI)Cases, *n*458198260Sex, *n* (%) Female286 (62.4)121 (61.1)165 (63.5)0.905 (0.618--1.325)0.853 (0.558--1.303) Male172 (37.6)77 (38.9)95 (36.5)Ref.Age (years), mean ± SD, (range)83.2 ± 6.6 (65--99)83.2 ± 6.383.3 ± 6.80.998 (0.970--1.026)1.008 (0.977--1.040)Number of medications at admission, mean ± SD, (range)7.7 ± 3.5 (0--20)9.4 ± 3.36.5 ± 3.21.311 (1.227--1.402)1.312 (1.227--1.403)MMSE^a^ (0--30), mean ± SD, (range)19.8 ± 4.7 (7--29)19.5 ± 4.720.0 ± 4.70.979 (0.916--1.047)--Type of accommodation, *n* (%) Nursing home151 (33.0)62 (31.3)89 (34.2)0.876 (0.590--1.300)-- Living at home307 (67.0)136 (68.7)171 (65.8)Ref.Geographic location, *n* (%) Skellefteå120 (26.2)45 (22.7)75 (28.8)0.725 (0.473--1.112)-- Umeå338 (73.8)153 (77.3)185 (71.2)Ref.*CI* confidence interval, *DDI(s)* drug--drug interaction(s), *MMSE* Mini-Mental State Examination, *OR* odds ratio, *Ref* reference category, *SD* standard deviationThe multiple analysis includes sex, age and significant variables from the simple model (number of medications at admission)^a^*n* = 162 because the test was not performed on every patient

A total of 401 clinically relevant DDIs were identified among the study sample of which 385 (96.0%) required dose adjustment and 16 (4.0%) cases involved drug combinations that should be avoided. Pharmacodynamic interactions were the most common type of identified interactions---187/401 (46.6%). Pharmacokinetic interactions accounted for 169/401 (42.1%) of the identified DDIs. Additive and synergistic interactions, 185/187 (98.9%), accounted for the vast majority of pharmacodynamic interactions. Furosemide--citalopram, 35/187 (18.7%), and acetylsalicylic acid--citalopram, 32/187 (17.1%), were the most common drug combinations found among pharmacodynamic interactions. Drug absorption interactions were the largest subclass, 83/169 (49.1%) among pharmacokinetic interactions. Omeprazole--citalopram, 25/169 (14.8%), and calcium--levothyroxine, 22/169 (13.0%), were the most common drug combinations among pharmacokinetic DDIs. Increased risk of bleeding and reduced efficacy were the most common potential clinical consequences of the identified DDIs (Table [4](#Tab4){ref-type="table"}).Table 4Frequency of clinically relevant DDIs, their pharmacological and clinical classification and potential consequenceClassification pharmacologicalClassification clinical/documentationDrug combination (frequency)Potential clinical consequence1. Pharmacokinetic interactions (*n* = 169)1.1 Drug absorption interactions (*n* = 83)C3Calcium + alendronic acid (13)Reduction of efficacy of alendronic acidC3Calcium + levothyroxine (22)Reduction of efficacy of levothyroxineC3Calcium + iron (15)Reduction of efficacy of ironC0Calcium + risedronic acid (2)Reduction of efficacy of risedronic acidD3Colestyramine + furosemide (1)Reduction of efficacy of furosemideC4Iron + levothyroxine (8)Reduction of efficacy of levothyroxineC3Iron + levodopa (2)Reduction of efficacy of levodopaC0Iron + alendronic acid (2)Reduction of efficacy of alendronic acidC0Iron + risedronic acid (1)Reduction of efficacy of risedronic acidC3Iron + aluminium (1)Reduction of efficacy of ironC3Iron + sodium hydrogen carbonate (13)Reduction of efficacy of ironC3Magnesium + mycophenolic acid (1)Reduction of efficacy of mycophenolic acidC1Magnesium + calcium polystyrene sulphonate (1)Increased risk of systemic metabolic alkalosisC3Omeprazole + levothyroxine (1)Reduction of efficacy of levothyroxine1.2.1 Drug metabolism interactions, enzyme induction (*n* = 15)C2Azathioprine + warfarin (1)Reduction in clinical efficacy of warfarinC3Carbamazepine + acetaminophen (1)Increased risk of liver damageC1Carbamazepine + atorvastatin (1)Reduction in clinical efficacy of atorvastatinC2Carbamazepine + cholecalciferol (2)Reduction in clinical efficacy of cholecalciferolC4Carbamazepine + citalopram (2)Reduction in clinical efficacy of citalopramD0Carbamazepine + diazepam (1)Reduction in clinical efficacy of diazepamD3Carbamazepine + felodipine (1)Reduction in clinical efficacy of felodipineC4Carbamazepine + olanzapine (1)Reduction in clinical efficacy of olanzapineD0Carbamazepine + ticagrelor (1)Reduction in clinical efficacy of ticagrelorC3Phenytoin + acetaminophen (1)Reduction in clinical efficacy of acetaminophen, increased risk of liver damageC3Phenytoin + mirtazapine (1)Reduction in clinical efficacy of mirtazapineC1Phenytoin + simvastatin (1)Reduction in clinical efficacy of simvastatinC3Prednisolone + tacrolimus (1)Reduction in clinical efficacy of tacrolimus1.2.2 Drug metabolism interactions, enzyme inhibition (*n* = 66)C3Amiodarone + simvastatin (1)Increased efficacy of simvastatin, risk of myopathyC4Amiodarone + metoprolol (2)Increased risk of hypotension, bradycardia or cardiac arrestC1Atorvastatin + diltiazem (1)Increased efficacy of atorvastatin, risk of myopathyD2Budesonide + fluconazole (1)Increased plasma levels of budesonideC4Ciclosporin + felodipine (1)Increased plasma levels of felodipineC3Ciclosporin + cinacalcet (1)Increased efficacy of cinacalcetC0Cinacalcet + metoprolol (1)Increased efficacy of metoprololC0Clopidogrel + imatinib (1)Increased efficacy of imatinibC3Darunavir + atorvastatin (1)Increased efficacy of atorvastatin, risk of myopathyC0Darunavir + budesonide (1)Increased efficacy of budesonideD1Econazole + warfarin (1)Increased efficacy of warfarinC3Esomeprazole + clopidogrel (3)Reduction in clinical efficacy of clopidogrelC0Esomeprazole + escitalopram (1)Increased plasma levels of escitalopram, risk of QT prolongationC0Esomeprazole + citalopram (2)Increased plasma levels of citalopram, risk of QT prolongationC0Fluconazole + clopidogrel (1)Reduction in clinical efficacy of clopidogrelD2Fluconazole + citalopram (1)Increased plasma levels of citalopram, risk of QT prolongationC3Hydroxychloroquine + metoprolol (1)Increased efficacy of metoprololC0Imatinib + atorvastatin (1)Increased efficacy of atorvastatin, risk of myopathyC3Mirabegron + metoprolol (2)Increased efficacy of metoprolol, risk of hypotension and bradycardiaC3Omeprazole + citalopram (25)Increased plasma levels of citalopram, risk of QT- prolongationC3Omeprazole + clopidogrel (7)Reduction in clinical efficacy of clopidogrelC3Omeprazole + escitalopram (4)Increased plasma levels of escitalopram, risk of QT-prolongationC2Omeprazole + tacrolimus (1)Increased efficacy of tacrolimusC0Paroxetine + timolol (1)Increased efficacy of timololC3Phenytoin + losartan (1)Reduction in clinical efficacy of losartanC4Ritonavir + atorvastatin (1)Increased efficacy of atorvastatin, risk of myopathyC2Ritonavir + budesonide (1)Increased efficacy of budesonideD4Warfarin + sulfamethoxazole^a^ (1)Increased risk of bleeding1.3 Drug excretion interactions (*n* = 5)C3Spironolactone + digoxin (4)Increased plasma levels of digoxin, risk of digoxin toxicityC1Furosemide + lithium (1)Decreased urinary excretion of lithium, risk of lithium toxicity2. Pharmacodynamic interactions (*n* = 187)2.1 Additive or synergistic interactions (*n* = 185)C0Acetylsalicylic acid + venlafaxine (2)Increased risk of bleedingC4Acetylsalicylic acid + sertraline (9)Increased risk of bleedingC4Acetylsalicylic acid + escitalopram (2)Increased risk of bleedingC4Acetylsalicylic acid + citalopram (32)Increased risk of bleedingC3Acetylsalicylic acid + ibuprofen (1)Increased risk of bleeding, reduced cardioprotective efficacyC0Clopidogrel + citalopram (8)Increased risk of bleedingC0Clopidogrel + escitalopram (2)Increased risk of bleedingC0Clopidogrel + paroxetine (1)Increased risk of bleedingC0Clopidogrel + sertraline (6)Increased risk of bleedingC0Clopidogrel + tramadol (1)Increased risk of bleedingC0Clopidogrel + venlafaxine (1)Increased risk of bleedingC0Dalteparin + escitalopram (1)Increased risk of bleedingC0Dalteparin + citalopram (1)Increased risk of bleedingC0Dalteparin + sertraline (1)Increased risk of bleedingC0Dipyridamole + citalopram (3)Increased risk of bleedingC4Ibuprofen + citalopram (1)Increased risk of bleedingC0Fondaparinux + citalopram (1)Increased risk of bleedingD4Warfarin + diclofenac (1)Increased risk of bleedingC3Warfarin + levothyroxine (10)Increased risk of bleedingC4Warfarin + citalopram (11)Increased risk of bleedingC1Warfarin + prednisolone (7)Increased risk of bleedingC2Warfarin + sertraline (1)Increased risk of bleedingC2Bendroflumethiazide + citalopram (3)Increased risk of hyponatraemiaC2Furosemide + escitalopram (1)Increased risk of hyponatremiaC2Furosemide + citalopram (35)Increased risk of hyponatraemiaC2Furosemide + sertraline (9)Increased risk of hyponatraemiaC3Hydrochlorothiazide + citalopram (2)Increased risk of hyponatraemiaC4Amiloride + enalapril (1)Increased risk of hyperkalaemiaC4Spironolactone + candesartan (1)Increased risk of hyperkalaemiaC4Spironolactone + enalapril (11)Increased risk of hyperkalaemiaC4Spironolactone + losartan (7)Increased risk of hyperkalaemiaC3Spironolactone + potassium (1)Increased risk of hyperkalaemiaC4Spironolactone + ramipril (2)Increased risk of hyperkalaemiaD0Ciprofloxacin + escitalopram (1)Increased risk of QT- prolongationD0Ciprofloxacin + citalopram (1)Increased risk of QT- prolongationD0Citalopram + donepezil (2)Increased risk of QT- prolongationD1Citalopram + haloperidol (1)Increased risk of QT- prolongationD0Diltiazem + timolol (1)Increased risk of hypotension, bradycardia or cardiac arrestD0Verapamil + timolol (1)Increased risk of hypotension, bradycardia or cardiac arrestC3Methotrexate + sulfamethoxazole^a^ (1)Additive, antagonistic effect on folic acid synthesisC3Methotrexate + trimethoprim^a^ (1)Additive, antagonistic effect on folic acid synthesis2.2 Antagonistic or opposing interactions (*n* = 2)C4Furosemide + diclofenac (1)Decreased effect of loop diuretics leading to decreased diuresis and worsening of heart failureC0Diclofenac + carvedilol (1)Decreased effect of beta-blocking agents3. Classification uncertain (*n* = 45)C4Ciclosporin + pravastatin (1)Increased efficacy of pravastatin, risk of myopathyC4Warfarin + acetaminophen (26)Increased risk of bleedingC3Morphine + gabapentin (1)Increased risk of CNS-symptomsC0Ramipril + darbepoetin alfa (1)Decreased responsiveness to darbepoetin alfaC4Warfarin + simvastatin (16)Increased efficacy of warfarin, risk of bleedingC = interaction which may require dose adjustmentD = interaction which should be avoided0--4 = level of documentation according to Table [1](#Tab1){ref-type="table"}^a^Combined formulation: trimethoprim/sulfamethoxazole

Citalopram and warfarin were the most commonly involved drug substances among the clinically relevant DDIs in both C and D interactions (Table [5](#Tab5){ref-type="table"}).Table 5Identified drug substances and their frequency of involvement in clinically relevant DDIs, category C and DDrugDDI(s) category C, *n* (%)^a^DDI(s) category D, *n* (%)^b^Acetaminophen28 (7.3)Acetylsalicylic acid46 (11.9)Alendronic acid15 (3.9)Aluminium1 (0.3)Amiloride1 (0.3)Amiodarone3 (0.8)Atorvastatin5 (1.3)Azathioprine1 (0.3)Bendroflumethiazide3 (0.8)Budesonide2 (0.5)1 (6.3)Calcium52 (13.5)Calcium polystyrene sulphonate1 (0.3)Candesartan1 (0.3)Carbamazepine7 (1.8)3 (18.8)Carvedilol1 (0.3)Cholecalciferol2 (0.5)Ciclosporin3 (0.8)Cinacalcet2 (0.5)Ciprofloxacin2 (12.5)Citalopram126 (32.7)5 (31.3)Clopidogrel31 (8.1)Colestyramine1 (6.3)Dalteparin3 (0.8)Darbepoetin alfa1 (0.3)Darunavir2 (0.5)Diazepam1 (6.3)Diclofenac2 (0.5)1 (6.3)Digoxin4 (1.0)Diltiazem1 (0.3)1 (6.3)Dipyridamole3 (0.8)Donepezil2 (12.5)Econazole1 (6.3)Enalapril12 (3.1)Escitalopram11 (2.9)1 (6.3)Esomeprazole6 (1.6)Felodipine1 (0.3)1 (6.3)Fluconazole1 (0.3)2 (12.5)Fondaparinux1 (0.3)Furosemide47 (12.2)1 (6.3)Gabapentin1 (0.3)Haloperidol1 (6.3)Hydrochlorothiazide2 (0.5)Hydroxychloroquine1 (0.3)Ibuprofen2 (0.5)Imatinib2 (0.5)Iron42 (10.9)Levodopa2 (0.5)Levothyroxine41 (10.6)Lithium1 (0.3)Losartan8 (2.1)Magnesium2 (0.5)Methotrexate2 (0.5)Metoprolol6 (1.6)Mirabegron2 (0.5)Mirtazapine1 (0.3)Morphine1 (0.3)Mycophenolic acid1 (0.3)Olanzapine1 (0.3)Omeprazole38 (9.9)Paroxetine2 (0.5)Phenytoin4 (6.2)Potassium1 (0.3)Pravastatin1 (0.3)Prednisolone8 (2.1)Ramipril3 (0.8)Risedronic acid3 (0.8)Ritonavir2 (0.5)Sertraline26 (6.8)Simvastatin18 (4.7)Sodium hydrogen carbonate13 (3.4)Spironolactone26 (6.8)Sulfamethoxazole1 (0.3)1 (6.3)Tacrolimus2 (0.5)Ticagrelor1 (6.3)Timolol1 (0.3)2 (12.5)Tramadol1 (0.3)Trimethoprim1 (0.3)Venlafaxine3 (0.8)Verapamil1 (6.3)Warfarin72 (18.7)3 (18.8)*C* interaction, which may require dose adjustment, *D* interaction, which should be avoided, *DDI(s)* drug--drug interaction(s)^a^Based on the total number of clinically relevant DDIs, category C, *n* = 385^b^Based on the total number of clinically relevant DDIs, category D, *n* = 16

Discussion {#Sec8}
==========

In the current study, almost half of the individuals with dementia or cognitive impairment admitted to hospital had at least one potentially clinically relevant DDI, which can be regarded as a high proportion being at risk of experiencing adverse drug reactions. The prevalence of people with potentially clinically relevant DDIs in the present study is, however, in the middle range compared to other studies \[[@CR12], [@CR20]--[@CR22]\]. Different study designs, settings and inclusion criteria might explain the different prevalence of DDIs \[[@CR24], [@CR25]\]. Another explanation for the difference might be the extensive work on medication reviews in the county, which lower potentially clinically relevant DDIs among the study sample \[[@CR26]\]. The prevalence is, however, still high and indicates an opportunity for further improvement.

The average number of drugs at the time of admission was higher among participants in the present study compared to other studies \[[@CR12], [@CR22], [@CR25]\]. It is known that elderly people, and especially those with dementia, take on average more medications than people without dementia \[[@CR27]\], which may be due to multiple comorbidities, experienced symptoms and misinterpretation of adverse drug reactions, resulting in new prescribed medications \[[@CR24]\]. This might explain the high average of drug use compared to other studies, a risk factor that has been found to have associations with the presence and increased risk of having DDIs \[[@CR12], [@CR24], [@CR25], [@CR28], [@CR29]\], which was also found in the present study. No association was found in the present study between sex and the presence of DDI. This result is consistent with other studies stating the same result \[[@CR13], [@CR29]\]. Conflicting results were, however, found in another study which stated that DDIs are more common in men than in women \[[@CR19]\]. No association was found in the present study between age and having one or more DDI. Another study found that a younger age was associated with the presence of DDIs \[[@CR13]\]. Different study settings may explain the different results. No association was found between MMSE score and having DDIs, which is consistent with previous results \[[@CR25]\]. Nor were any associations found in the present study between living accommodation and geographic location, and the presence of one or more DDIs.

Most of the interactions in the present study required dose adjustment or some monitoring in order to prevent adverse drug reactions (C interactions). Furosemide--citalopram and acetylsalicylic acid--citalopram were the most common DDIs among pharmacodynamic interactions. If not monitored correctly, their additive or synergistic interaction may lead to hyponatraemia and increased risk of bleeding, respectively \[[@CR17]\]. Omeprazole--citalopram and calcium--levothyroxine were the most common pharmacokinetic interactions leading to prolongation of QT interval due to enzyme inhibition and reduced efficacy due to absorption interactions. Warfarin--acetaminophen were also among the most common DDIs found in the present study leading to increased risk of bleeding if no dose adjustments were made \[[@CR17]\]. The C interactions found in the present study differ both in prevalence and from the most common DDIs identified in other studies, in which citalopram--antiplatelet, non-steroidal anti-inflammatory drugs (NSAIDs)--beta-blocking agents, angiotensin-converting enzyme (ACE) inhibitors--NSAIDs and digoxin--furosemide were the most commonly reported interactions \[[@CR12], [@CR20]--[@CR22], [@CR29]\]. The low prevalence of interactions involving NSAIDs in the present study might be attributable to information campaigns to physicians and medication reviews performed on people living in nursing homes in the county of Västerbotten \[[@CR30]\].

Even if a small proportion of the study population had interactions that should be avoided (D interactions), it warrants concern because of the difficulty in managing these interactions compared to C interactions \[[@CR31]\]. Citalopram--donepezil was the most common D interaction in the present study and this differs from the most common D interactions found in other studies \[[@CR13], [@CR19], [@CR20], [@CR29]\]. The reason for the difference is the specific study population in the present study. This severe interaction is therefore of concern specifically among people with dementia. Citalopram is commonly used to treat depression among elderly people with dementia in Sweden and the drug can lead to a prolongation of the QT interval that is not seen among all serotonin selective reuptake inhibitors (SSRI). Together with donepezil, an additive prolongation effect on QT interval may lead to torsades de pointes, a serious side effect \[[@CR17]\]. Further, it is recommended that SSRI is used instead of antipsychotic drugs to treat behavioural and psychological symptoms in dementia (BPSD) when non-pharmacological interventions or treatment with memantine do not work effectively \[[@CR32]\]. Citalopram was the most commonly involved drug substance among the identified DDIs in the present study. This is consistent with a study which found that psychotropic drug use was commonly involved in DDIs among elderly people with dementia \[[@CR22]\]. Another study found an association between depression and having one or more DDIs \[[@CR12]\]. It is therefore important to regularly evaluate the need for antidepressants and monitor the side effects, e.g. increased risk of bleeding and hyponatraemia due to potential DDIs, which may arise with other concomitant drugs, especially among elderly people with dementia \[[@CR32], [@CR33]\]. Warfarin was the second most commonly involved drug among the DDIs in the present study. Its increased anticoagulant effect among elderly people, significant dose-response variability, narrow therapeutic index and the difficulties with compliance that are sometimes experienced among people with dementia make DDIs involving warfarin additionally complex and important to monitor to avoid increased risk of bleeding \[[@CR1], [@CR34], [@CR35]\]. Warfarin treatment is usually well monitored, which fortunately reduces the risks of adverse outcomes \[[@CR36]\].

The most common clinical consequences were increased risk of bleeding, reduced efficacy of involved drugs and electrolyte disturbances, which may have been caused by the identified interactions in the present study. Some of the identified interactions also led to hospitalisation, which was mentioned in another study investigating drug-related hospital admissions \[[@CR7]\] among the same study sample as in the present study. In that study, it was found that 6.9% of hospital admissions were due to drug--drug interactions \[[@CR7]\]. Increased risk of bleeding is of special concern among elderly people \[[@CR35]\] and particularly among those with dementia because the clinical presentation may be atypical and involve confusion. The adverse outcome is then particularly difficult to identify \[[@CR34]\]. Some cases may be monitored via laboratory tests, dose adjustments or additional drug therapy, e.g. proton pump inhibitors (PPIs) to prevent bleeding. This may, however, increase the risk of DDIs depending on the drug chosen. Electrolyte disturbances are important to identify and manage particularly when new drug treatments are introduced and among elderly women who are more vulnerable to hyponatraemia, for example \[[@CR17]\]. Increased risk of bleeding and electrolyte disturbances were also the most common reasons for hospital admission due to DDIs among the present study sample \[[@CR7]\]. ADRs and reduced efficacy may be identified and managed among those living in nursing homes but might result in reduced quality of life among people living at home, as they are unable to identify and communicate adverse outcomes by themselves.

The following limitations should be recognised. Drugs with pro re nata dosage were excluded, which may lower the prevalence of clinically relevant DDIs in the present study. Even if the DDIs were categorised as clinically relevant, the prevalence of interactions may not reflect their true clinical relevance. We did not know if doses had been correctly adjusted, e.g. warfarin--acetaminophen, if drugs were taken separately when this was recommended, e.g. calcium--levothyroxine, or if the drug combination was appropriate according to the clinical indication, e.g. spironolactone--enalapril in individuals with congestive heart failure \[[@CR17]\]. Nor was it possible to evaluate causality or outcome due to the cross-sectional study design. It was only possible to check interactions pairwise \[[@CR18]\]. Interactions from more than two substances have therefore not been identified. Moreover, only some specific pharmacodynamic interactions have been included in the database \[[@CR18]\].

The strength of the present study is that the result can be considered as representative for people 65 years or older with dementia because no other inclusion or exclusion criteria were applied. Out of 473 invited people, only two were excluded and only 13 declined to participate. Moreover, medical records are a reliable source of information in a cross-sectional study \[[@CR37]\]. The Janusmed interaction database is a regularly updated DDI identification tool used in clinical practice in Sweden \[[@CR18]\].

Conclusion {#Sec9}
==========

Clinically relevant DDIs are prevalent among elderly people with dementia in Northern Sweden and interactions requiring dose adjustment are most common. Thus, identification and clinical and laboratory assessments of DDIs are crucial in order to manage and prevent adverse outcomes among elderly people with dementia, especially when multiple medications are being prescribed.
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